SPOTLIGHT: The top five regions targeting biotech


This year's list of top economic development efforts for biotechnology stays focused on the U.S., with five states that have stepped up to the plate with offers of significant financial support designed to spawn a new generation of drug developers. In many cases, these state programs are driving the development of new facilities that will likely have a profound impact in determining where the industry will find its most fertile soil for future growth. List

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.